INDUSTRY POSITION Target the biotechnology and oncology space by emphasizing Enara Bio's first-in-class ENA101 darkfox-targeting bispecific T cell engager and their EDAPT Dark Antigen discovery platform as sources of novel solid tumor targets for potential partnerships or licensing deals.

INDUSTRY COLLAB Leverage Boehringer Ingelheim as a collaborator example and propose expansion of co-development opportunities, as Enara Bio already pursues partnerships to combine licensed Dark Antigens into novel immunotherapies.

INDUSTRY EXPANSION Position Enara Bio for geographic and therapeutic expansion by highlighting ongoing IND-enabling studies and upcoming IND filing in H2 2026, offering services or syndicate investment opportunities around late-stage readiness.

FINANCIAL READINESS Align sales efforts with Enara Bio’s funding and revenue profile (mid-market biotech with substantial funding and a growing revenue base) to propose sponsored research, milestone-based partnerships, or co-development financing structures.

REVIEW & TALENT Engage through executive-level introductions (CEO Dr. Pojasek and newly appointed CMO Dr. Scott Drutman) to discuss strategic collaborations, clinical strategy alignment, and potential advisory or consulting roles that could accelerate clinical programs.